Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products. The Company"s products include implants, biologics, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, communications and digital imaging systems, as well as patient handling and emergency medical equipment.
Website: stryker.com



Growth: Good revenue growth rate 11.8%, there is slowdown compared to average historical growth rates 13.5%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -12.0%

Profitability: LTM EBITDA margin is positive, +19.0%. On average the margin is improving unsteadily. Gross margin is high, +63.7%. In the last quarter the company beat the estimated EPS, +7.0%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.9%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 89.1% higher than minimum and 0.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.1x by EV / Sales multiple , the company can be 53.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $7.2 mln (-0.005% of cap.)

Key Financials (Download financials)

Ticker: SYK
Share price, USD:  (-0.2%)357.87
year average price 297.81  


year start price 285.47 2023-03-31

min close price 253.85 2023-10-12

max close price 358.71 2024-03-27

current price 357.87 2024-03-29
Common stocks: 378 200 000

Dividend Yield:  0.9%
FCF Yield LTM: 0.0%
EV / LTM EBITDA: 34.8x
EV / EBITDA annualized: 26.9x
Last revenue growth (y/y):  11.8%
Last growth of EBITDA (y/y):  54.4%
Historical revenue growth:  13.5%
Historical growth of EBITDA:  17.7%
EV / Sales: 6.6x
Margin (EBITDA LTM / Revenue): 19.0%
Fundamental value created in LTM:
Market Cap ($m): 135 346
Net Debt ($m): 8
EV (Enterprise Value): 135 354
Price to Book: 7.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-27Zacks Investment Research

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

2024-03-22Zacks Investment Research

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

2024-03-21Zacks Investment Research

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

2024-03-06Zacks Investment Research

Stryker (SYK) Completes First Arthroplasty Surgery in Europe

2024-02-07Seeking Alpha

Stryker: Rerating Higher

2024-02-02Seeking Alpha

Stryker: A Dividend Growth Powerhouse I'd Like To Own

2024-01-31CNBC Television

Stryker CEO Kevin Lobo on M&A goals in 2024

2024-01-31Zacks Investment Research

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

2024-01-30Seeking Alpha

Stryker Corporation (SYK) Q4 2023 Earnings Call Transcript

2024-01-30Zacks Investment Research

Stryker (SYK) Reports Q4 Earnings: What Key Metrics Have to Say
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SYK SYK SYK SYK SYK SYK
reportedCurrency USD USD USD USD USD USD
cik 310 764 310 764 310 764 310 764 310 764 310 764
fillingDate 2024-02-14 2023-11-03 2023-08-04 2023-05-02 2023-02-10 2022-11-01
acceptedDate 2024-02-14 10:55:50 2023-11-03 11:23:21 2023-08-04 11:16:14 2023-05-02 14:07:18 2023-02-10 16:18:01 2022-11-01 14:28:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 5 815M 4 909M 4 996M 4 778M 5 202M 4 479M
costOfRevenue 2 112M 1 751M 1 815M 1 762M 1 966M 1 697M
grossProfit 3 703M 3 158M 3 181M 3 016M 3 236M 2 782M
grossProfitRatio 0.637 0.643 0.637 0.631 0.622 0.621
researchAndDevelopmentExpenses 350M 353M 346M 339M 326M 364M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 941M 1 701M 1 706M 1 781M 1 751M 1 455M
otherExpenses -31M -62M -66M 161M 158M 159M
operatingExpenses 2 440M 2 218M 2 213M 2 281M 2 235M 1 978M
costAndExpenses 4 552M 3 969M 4 028M 4 043M 4 201M 3 675M
interestIncome 35M 15M 0 0 0 0
interestExpense 0 0 0 56M 53M 0
depreciationAndAmortization 250M 262M 259M 257M 253M 258M
ebitda 1 519M 1 211M 1 230M 992M 1 441M 1 066M
ebitdaratio 0.261 0.247 0.246 0.208 0.277 0.238
operatingIncome 1 257M 931M 965M 735M 1 188M 808M
operatingIncomeRatio 0.216 0.190 0.193 0.154 0.228 0.180
totalOtherIncomeExpensesNet -37M -71M -69M -56M -427M 8M
incomeBeforeTax 1 226M 869M 899M 679M 761M 816M
incomeBeforeTaxRatio 0.211 0.177 0.180 0.142 0.146 0.182
incomeTaxExpense 83M 177M 161M 87M 198M -8M
netIncome 1 143M 692M 738M 592M 563M 816M
netIncomeRatio 0.197 0.141 0.148 0.124 0.108 0.182
eps 3.010 1.820 1.950 1.560 1.480 2.160
epsdiluted 2.980 1.800 1.930 1.540 1.470 2.140
weightedAverageShsOut 380M 380M 380M 379M 379M 378M
weightedAverageShsOutDil 384M 384M 384M 383M 382M 382M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SYK SYK SYK SYK SYK SYK
reportedCurrency USD USD USD USD USD USD
cik 310 764 310 764 310 764 310 764 310 764 310 764
fillingDate 2024-02-14 2023-11-03 2023-08-04 2023-05-02 2023-02-10 2022-11-01
acceptedDate 2024-02-14 10:55:50 2023-11-03 11:23:21 2023-08-04 11:16:14 2023-05-02 14:07:18 2023-02-10 16:18:01 2022-11-01 14:28:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 2 971M 1 860M 1 401M 1 671M 1 844M 1 420M
shortTermInvestments 82M 76M 77M 86M 84M 77M
cashAndShortTermInvestments 3 053M 1 936M 1 478M 1 757M 1 928M 1 497M
netReceivables 3 765M 3 276M 3 261M 3 215M 3 565M 3 103M
inventory 4 843M 4 883M 4 593M 4 333M 3 995M 3 883M
otherCurrentAssets 857M 950M 819M 850M 787M 835M
totalCurrentAssets 12 518M 11 045M 10 151M 10 155M 10 275M 9 318M
propertyPlantEquipmentNet 3 215M 3 106M 3 082M 3 037M 2 970M 2 798M
goodwill 15 243M 15 138M 15 172M 14 849M 14 880M 14 993M
intangibleAssets 4 593M 4 731M 4 917M 4 779M 4 885M 5 053M
goodwillAndIntangibleAssets 19 836M 19 869M 20 089M 19 628M 19 765M 20 046M
longTermInvestments 2M 12M 0 0 0 0
taxAssets 1 670M 1 406M 1 439M 1 443M 1 410M 1 390M
otherNonCurrentAssets 2 671M 2 604M 2 648M 2 567M 2 464M 2 431M
totalNonCurrentAssets 27 394M 26 997M 27 258M 26 675M 26 609M 26 665M
otherAssets 0 0 0 0 0 0
totalAssets 39 912M 38 042M 37 409M 36 830M 36 884M 35 983M
accountPayables 1 517M 1 296M 1 326M 1 366M 1 413M 1 213M
shortTermDebt 2 094M 10 382M 11 149M 1 204M 1 191M 8M
taxPayables 391M 465M 469M 371M 292M 243M
deferredRevenue 7 321M -1 296M -1 326M 0 1 410M 0
otherCurrentLiabilities -3 011M -2 924M -4 565M 3 296M 2 289M 3 350M
totalCurrentLiabilities 7 921M 7 458M 6 584M 5 866M 6 303M 4 571M
longTermDebt 10 901M 10 382M 11 149M 11 857M 11 857M 12 751M
deferredRevenueNonCurrent -63M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 63M 0 0 0 0 1 390M
otherNonCurrentLiabilities 2 497M 2 297M 2 315M 2 212M 2 108M 13 728M
totalNonCurrentLiabilities 13 398M 12 679M 13 464M 14 069M 13 965M 14 949M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 356M 369M 0 0 0 0
totalLiabilities 21 319M 20 137M 20 048M 19 935M 20 268M 19 520M
preferredStock 0 0 0 0 0 0
commonStock 38M 38M 38M 38M 38M 38M
retainedEarnings 16 771M 15 933M 15 526M 15 072M 14 765M 14 486M
accumulatedOtherComprehensiveIncomeLoss -416M -249M -330M -305M -221M -89M
othertotalStockholdersEquity 2 200M 2 183M 2 127M 2 090M 2 034M 2 028M
totalStockholdersEquity 18 593M 17 905M 17 361M 16 895M 16 616M 16 463M
totalEquity 18 593M 17 905M 17 361M 16 895M 16 616M 16 463M
totalLiabilitiesAndStockholdersEquity 39 912M 38 042M 37 409M 36 830M 36 884M 35 983M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 39 912M 38 042M 37 409M 36 830M 36 884M 35 983M
totalInvestments 82M 76M 77M 86M 84M 77M
totalDebt 12 995M 10 382M 11 149M 11 857M 13 048M 12 759M
netDebt 10 024M 8 522M 9 748M 10 186M 11 204M 11 339M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SYK SYK SYK SYK SYK SYK
reportedCurrency USD USD USD USD USD USD
cik 310 764 310 764 310 764 310 764 310 764 310 764
fillingDate 2024-02-14 2023-11-03 2023-08-04 2023-05-02 2023-02-10 2022-11-01
acceptedDate 2024-02-14 10:55:50 2023-11-03 11:23:21 2023-08-04 11:16:14 2023-05-02 14:07:18 2023-02-10 16:18:01 2022-11-01 14:28:18
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 143M 692M 738M 592M 563M 816M
depreciationAndAmortization 250M 262M 259M 257M 253M 250M
deferredIncomeTax -182M 0 0 0 0 0
stockBasedCompensation 40M 100 000 200 000 74M 28M 33M
changeInWorkingCapital 278M 192M -247M -404M 187M -217M
accountsReceivables -441M -42M -57M 365M -393M -27M
inventory 125M -333M -275M -314M -8M -231M
accountsPayables 195M -21M -41M -56M 179M 77M
otherWorkingCapital 399M 588M 126M -399M 409M -36M
otherNonCashItems -1 000 000 -96M -62M -74M -28M 7M
netCashProvidedByOperatingActivities 1 528M 1 050M 688M 445M 1 003M 889M
investmentsInPropertyPlantAndEquipment -145M -148M -152M -130M -188M -138M
acquisitionsNet 0 -1 000 000 -390M 0 0 0
purchasesOfInvestments -11M -6M -7M -28M -9M -5M
salesMaturitiesOfInvestments 5M 7M 17M 25M 3M 208M
otherInvestingActivites -1 000 000 3M -1 000 000 1 000 000 32M 7M
netCashUsedForInvestingActivites -152M -145M -533M -132M -162M 72M
debtRepayment -1 206M -651M -101M -102M -151M -250M
commonStockIssued 0 4M -2M 0 0 0
commonStockRepurchased 0 651M 101M 0 0 0
dividendsPaid -285M -285M -285M -284M -263M -263M
otherFinancingActivites 1 205M -141M -118M -95M -32M -30M
netCashUsedProvidedByFinancingActivities -286M -422M -405M -481M -446M -543M
effectOfForexChangesOnCash 21M -24M -20M -5M 29M -42M
netChangeInCash 1 111M -942M -1 941M -2 017M 424M 376M
cashAtEndOfPeriod 2 971M 459M -270M -173M 1 844M 1 420M
cashAtBeginningOfPeriod 1 860M 1 401M 1 671M 1 844M 1 420M 1 044M
operatingCashFlow 1 528M 1 050M 688M 445M 1 003M 889M
capitalExpenditure -145M -148M -152M -130M -188M -138M
freeCashFlow 1 383M 902M 536M 315M 815M 751M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-01-30 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-01-31 ET (fiscal 2022 q4)
2022 q3
2022-10-31 ET (fiscal 2022 q3)
2022 q2
2022-07-26 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-31 13:10 ET
Stryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and Ankle
2024-01-30 21:05 ET
Stryker reports 2023 operating results and 2024 outlook
2024-01-17 13:00 ET
New Intermediate Nail and RC Lag Screw Expand Gamma4 Portfolio to Meet the Needs of Surgeons and Their Patients
2024-01-10 13:35 ET
First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph’s Health Care London in Canada
2024-01-08 13:00 ET
Stryker announces 2023 sales surpassed $20 billion
2024-01-05 13:00 ET
Stryker to announce financial results for its fourth quarter and full year 2023
2023-12-18 14:00 ET
Stryker announces intent to acquire SERF SAS, enhancing its global joint replacement leadership
2023-12-07 13:00 ET
Stryker announces intention to nominate a new director, Rachel Ruggeri
2023-12-06 13:00 ET
Stryker announces Dr. Srikant Datar will retire from Board of Directors
2023-12-05 13:00 ET
Stryker declares a $0.80 per share quarterly dividend
2023-11-02 20:17 ET
Stryker reports third quarter 2023 operating results
2023-10-30 20:05 ET
Stryker to participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-10-12 12:35 ET
Over 2,400 Surgical Cases Completed Using Stryker’s Q Guidance System with Spine Guidance Software in First Year
2023-10-09 20:05 ET
Stryker to host investor day
2023-10-02 20:05 ET
Stryker to announce financial results for its third quarter of fiscal year 2023
2023-09-21 18:07 ET
Stryker's Triathlon Tritanium Baseplate marks a decade of positive patient impact
2023-09-19 13:20 ET
Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions
2023-09-14 12:03 ET
A Clearer Vision of Surgery: Stryker Releases its Next-Generation of Advanced Surgical Cameras
2023-09-12 13:20 ET
Stryker’s Pangea Systems Receive FDA Clearance
2023-08-07 20:05 ET
Stryker to participate in the 2023 Wells Fargo Securities Healthcare Conference
2023-08-04 12:02 ET
Stryker launches national direct-to-patient marketing campaign
2023-08-03 20:05 ET
Stryker reports second quarter 2023 operating results
2023-08-02 12:00 ET
Stryker declares a $0.75 per share quarterly dividend
2023-07-11 12:30 ET
Stryker Announces Commercial Launch of Q Guidance System With Cranial Guidance Software
2023-07-06 12:27 ET
Stryker launches industry's only fully autonomous guidance system
2023-06-30 20:05 ET
Stryker to announce financial results for its second quarter of fiscal year 2023
2023-05-24 12:30 ET
Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software
2023-05-10 17:01 ET
Stryker declares a $0.75 per share quarterly dividend
2023-05-02 12:00 ET
Stryker completes acquisition of Cerus Endovascular
2023-05-01 20:05 ET
Stryker reports first quarter 2023 operating results
2023-03-30 20:05 ET
Stryker to announce financial results for its first quarter of fiscal year 2023
2023-03-30 12:27 ET
Stryker Now Offers the Only FDA-Cleared Pyrocarbon Bearing Material Option for Shoulder Hemiarthroplasty
2023-03-28 17:12 ET
Stryker announces Annual Meeting of Shareholders
2023-03-02 13:13 ET
CD NXT power tool system empowers surgeons through real-time depth measurement
2023-02-17 14:30 ET
Stryker’s Q Guidance System for cranial applications receives FDA clearance
2023-02-09 13:00 ET
Stryker declares a $0.75 per share quarterly dividend
2023-01-31 21:05 ET
Stryker reports 2022 operating results and 2023 outlook
2022-12-28 21:05 ET
Stryker to host conference call on January 31, 2023
2022-12-13 15:27 ET
Stryker launches Citrefix™ Suture Anchor System, featuring award-winning Citregen biomaterial designed to support bone regeneration and the natural healing process
2022-12-07 13:00 ET
Stryker declares a $0.75 per share quarterly dividend
2022-11-14 12:00 ET
Stryker opens the OR of the Future for customers to experience tomorrow's OR today
2022-11-03 20:05 ET
Stryker to participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-10-31 20:05 ET
Stryker reports third quarter 2022 operating results
2022-10-12 12:45 ET
Stryker to Showcase Innovative Portfolio of Spine Solutions at the North American Spine Society Meeting
2022-10-04 12:45 ET
Stryker Launches Monterey AL Interbody System with New Pre-clinical Data
2022-09-29 20:05 ET
Stryker to host conference call on October 31, 2022
2022-09-27 12:45 ET
Stryker Launches Q Guidance System with Spine Guidance Software
2022-09-20 12:07 ET
Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System
2022-09-14 12:05 ET
Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting
2022-09-01 12:07 ET
Stryker Launches New Gamma4 Hip Fracture Nailing System
2022-08-22 20:05 ET
Stryker to participate in the 2022 Wells Fargo Securities Healthcare Conference
2022-08-03 12:00 ET
Stryker declares a $0.695 per share quarterly dividend
2022-07-26 20:05 ET
Stryker reports second quarter 2022 operating results
2022-06-30 14:04 ET
Stryker to host conference call on July 26, 2022
2022-06-28 12:33 ET
Stryker Launches “Free Your Feet” Campaign to Raise Awareness About New Bunion Treatments
2022-06-24 15:00 ET
Stryker's debut at World Intelligence Congress: Bringing Stryker's Advanced Digital Healthcare to China
2022-05-31 12:59 ET
Stryker Receives FDA Clearance for Q Guidance System for Spine Applications
2022-05-05 16:00 ET
Stryker announces new Investor Relations leader
2022-05-05 12:00 ET
Stryker announces board changes following Annual Meeting of Shareholders
2022-05-04 12:00 ET
Stryker declares a $0.695 per share quarterly dividend
2022-05-03 10:59 ET
Stryker's InSpace subacromial balloon spacer two-year, Level 1 randomized controlled clinical study published in the Journal of Bone and Joint Surgery
2022-05-02 20:05 ET
Stryker to participate in the Bank of America Securities 2022 Health Care Conference
2022-04-28 20:05 ET
Stryker reports first quarter 2022 operating results
2022-04-06 14:01 ET
SYK Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Stryker Corporation for Potential Securities Law Violations
2022-04-06 13:15 ET
Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Stryker Corp. (NYSE: SYK)
2022-03-30 13:00 ET
Stryker to host conference call on April 28, 2022
2022-03-24 19:10 ET
Stryker announces Annual Meeting of Shareholders
2022-02-25 21:30 ET
Vocera Communications, Inc. Announces Fundamental Change and Make-Whole Fundamental Change With Respect to its 1.50% Convertible Senior Notes due 2023 and 0.50% Convertible Senior Notes due 2026

SEC forms

Show financial reports only

SEC form 10
2024-02-14 00:00 ET
Stryker published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Stryker published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Stryker reported for 2023 q4
SEC form 10
2023-11-03 11:23 ET
Stryker published news for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Stryker published news for 2023 q3
SEC form 8
2023-11-02 16:20 ET
Stryker reported for 2023 q3
SEC form 10
2023-08-04 11:16 ET
Stryker published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Stryker published news for 2023 q2
SEC form 6
2023-08-03 16:12 ET
Stryker reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Stryker published news for 2023 q2
SEC form 6
2023-06-16 16:31 ET
Stryker published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Stryker published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Stryker published news for 2023 q1
SEC form 6
2023-03-01 17:47 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-13 17:35 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-13 17:29 ET
Stryker published news for 2022 q4
SEC form 10
2023-02-10 16:18 ET
Stryker reported for 2022 q4
SEC form 10
2023-02-10 00:00 ET
Stryker reported for 2022 q4
SEC form 6
2023-02-06 18:30 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-06 18:26 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-06 18:21 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-06 18:17 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-06 18:13 ET
Stryker published news for 2022 q4
SEC form 6
2023-02-06 18:08 ET
Stryker published news for 2022 q4
SEC form 6
2023-01-31 16:07 ET
Stryker published news for 2022 q4
SEC form 8
2023-01-31 00:00 ET
Stryker reported for 2022 q4
SEC form 6
2023-01-11 19:02 ET
Stryker published news for 2022 q4
SEC form 6
2022-12-07 16:07 ET
Stryker published news for 2022 q3
SEC form 6
2022-12-05 19:09 ET
Stryker published news for 2022 q3
SEC form 6
2022-11-15 16:20 ET
Stryker published news for 2022 q3
SEC form 10
2022-11-01 14:28 ET
Stryker reported for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Stryker reported for 2022 q3
SEC form 6
2022-10-31 16:14 ET
Stryker published news for 2022 q3
SEC form 8
2022-10-31 00:00 ET
Stryker reported for 2022 q3
SEC form 10
2022-07-27 13:17 ET
Stryker reported for 2022 q2
SEC form 10
2022-07-27 00:00 ET
Stryker reported for 2022 q2
SEC form 6
2022-07-26 16:15 ET
Stryker published news for 2022 q2
SEC form 8
2022-07-26 00:00 ET
Stryker reported for 2022 q2
SEC form 6
2022-05-09 15:41 ET
Stryker published news for 2022 q1
SEC form 6
2022-05-05 08:59 ET
Stryker published news for 2022 q1
SEC form 10
2022-04-29 10:48 ET
Stryker reported for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Stryker reported for 2022 q1
SEC form 6
2022-04-28 16:25 ET
Stryker published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Stryker reported for 2022 q1
SEC form 6
2022-03-23 14:48 ET
Stryker published news for 2021 q4
SEC form 6
2022-02-25 09:24 ET
Stryker published news for 2021 q4
SEC form 6
2022-02-23 16:31 ET
Stryker published news for 2021 q4
SEC form 10
2022-02-11 13:02 ET
Stryker published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
Stryker published news for 2021 q4
SEC form 6
2022-02-04 16:04 ET
Stryker published news for 2021 q4
SEC form 6
2022-02-04 15:59 ET
Stryker published news for 2021 q4
SEC form 6
2022-01-27 16:09 ET
Stryker published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
Stryker published news for 2021 q4
SEC form 6
2022-01-14 12:11 ET
Stryker published news for 2021 q4
SEC form 6
2022-01-11 17:06 ET
Stryker published news for 2021 q4
SEC form 6
2022-01-03 07:00 ET
Stryker published news for 2021 q4
SEC form 10
2021-10-29 10:58 ET
Stryker published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
Stryker published news for 2021 q3
SEC form 6
2021-10-28 16:08 ET
Stryker published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Stryker published news for 2021 q3
SEC form 6
2021-08-18 16:08 ET
Stryker published news for 2021 q2
SEC form 10
2021-07-28 14:16 ET
Stryker published news for 2021 q2
SEC form 10
2021-07-28 00:00 ET
Stryker published news for 2021 q2
SEC form 6
2021-07-27 16:47 ET
Stryker published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
Stryker published news for 2021 q2
SEC form 6
2021-05-11 14:30 ET
Stryker published news for 2021 q1
SEC form 10
2021-04-28 12:42 ET
Stryker published news for 2021 q1
SEC form 10
2021-04-28 00:00 ET
Stryker published news for 2021 q1
SEC form 6
2021-04-27 16:08 ET
Stryker published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Stryker published news for 2021 q1
SEC form 6
2021-03-24 14:35 ET
Stryker published news for 2020 q4
SEC form 10
2021-02-11 11:17 ET
Stryker published news for 2020 q4
SEC form 6
2021-02-05 08:42 ET
Stryker published news for 2020 q4
SEC form 6
2021-01-27 16:07 ET
Stryker published news for 2020 q4
SEC form 6
2020-12-03 15:45 ET
Stryker published news for 2020 q3
SEC form 6
2020-11-23 16:32 ET
Stryker published news for 2020 q3
SEC form 6
2020-11-16 16:27 ET
Stryker published news for 2020 q3
SEC form 6
2020-11-13 07:30 ET
Stryker published news for 2020 q3
SEC form 6
2020-11-09 07:34 ET
Stryker published news for 2020 q3
SEC form 10
2020-10-30 12:48 ET
Stryker published news for 2020 q3
SEC form 6
2020-10-29 16:09 ET
Stryker published news for 2020 q3